-------------------------------------------------------------------------
-------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited)
Three-month Three-month
period ended period ended
September 30, September 30,
2008 2007
$ $
-------------------------------------------------------------------------
REVENUES
Licensing fees - 32,811
-------------------------------------------------------------------------
- 32,811
-------------------------------------------------------------------------
EXPENSES
Research and development 3,782,048 2,765,799
General and administrative 1,548,098 1,332,181
Amortization 791,229 659,318
Foreign exchange gain (685,249) (29,030)
Loss on disposal of capital assets 10,294 -
-------------------------------------------------------------------------
5,446,420 4,728,268
-------------------------------------------------------------------------
Loss before the following: (5,446,420) (4,695,457)
Interest income from held-to-maturity
investments 413,624 596,479
---------------------------------------------
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved |